UNSPSC 51372320: Carfentanil citrate

This classification denotes an opioid receptor agonist with the molecular formula C24H30N2O3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LG286J8GV, chemically known as 4-piperidinecarboxylic acid, 4-((1-oxopropyl)phenylamino)-1-(2-phenylethyl)-, methyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) but more generally known as carfentanil citrate, which bears US NIH Compound Identifier 65496. Most nations, for tariff and trade purposes, schedule carfentanil citrate under HS 29333999 and SITC 51574.

As of Q4 2014, CARFENTANIL CITRATE remains US FDA's Preferred Term for this commodity. Carfentanil citrate bears US NLM identifiers UMLS ID C0108502 and NCI Concept Code C77280. SMILES: CCC(=O)N(C1CCCCC1)C2(CCN(CC2)CCC3CCCCC3)C(=O)OC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51372320 Carfentanil citrate is a Commodity code that state and local governments do not actively solicit under based on recent procurement records. The three most recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals — none of which center on carfentanil citrate as a line item or primary scope. The mismatch suggests either tagging error in the posting systems or that carfentanil citrate, a potent synthetic opioid used in specialized veterinary and medical applications, falls outside typical state and local procurement patterns. Issuing bodies in the recent record span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon), but their actual procurement focuses on harm-reduction products and generic pharmaceuticals for broad population distribution rather than controlled-substance manufacturing inputs.

No recent state and local solicitations materially concern carfentanil citrate procurement. The tagged opportunities reflect community health initiatives (naloxone distribution), pharmacy benefit program modernization (direct manufacturer contracting), and wholesale generic pharmaceutical supply agreements — categories orthogonal to the code's nominal scope. A firm evaluating this code for business development should treat it as inactive for state and local opportunity purposes and monitor whether future tagging corrections or genuine carfentanil citrate demand signals emerge in the procurement record.